EW — Edwards Lifesciences Corp
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1099800 ·
Last close
$85.19
Market Cap
$49.10B
52W High
$96.29
52W Low
$72.30
ADV30
3,233,738
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 1,569,600,000 | 1,226,600,000 | 370,300,000 | 91,200,000 | 13,697,200,000 | 2,938,000,000 | 3,359,600,000 |
| Sep 2025 | 1,553,100,000 | 1,207,900,000 | 425,100,000 | 291,100,000 | 13,272,200,000 | 2,685,600,000 | 3,067,200,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,358,600,000
Investing CF
$-891,000,000
Financing CF
$-1,150,000,000
CapEx
$-269,100,000
Dividends Paid
—
Buybacks
$-1,056,600,000
EPS Diluted TTM
$1.74
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$14,621,200,000
Inventory
$1,119,000,000
Receivables
$973,000,000
ST Investments
$1,226,000,000
EBIT TTM
$1,398,100,000
Pretax Income TTM
$1,298,000,000
Interest Exp TTM
—
Analysts
26
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,512,300,032
EBITDA
$1,996,800,000
Free Cash Flow
$1,232,412,544
Enterprise Value
$45,189,468,160
Total Cash
$4,252,699,904
Total Debt
$704,400,000
Shares Out
576,400,000
Trailing EPS
$1.68
Book Value
$18.41
ROE
9.2%
ROA
8.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,067,600,000 | 1,636,200,000 | 1,073,500,000 | 13,697,200,000 | 3,359,600,000 | 10,337,600,000 | 1,595,200,000 |
| Dec 2024 | 5,439,500,000 | 1,480,100,000 | 4,174,600,000 | 13,055,300,000 | 2,992,400,000 | 9,998,400,000 | 542,300,000 |
| Dec 2023 | 5,010,000,000 | 1,486,200,000 | 1,402,400,000 | 9,363,200,000 | 2,643,800,000 | 6,650,000,000 | 895,800,000 |
| Dec 2022 | 4,464,000,000 | 1,539,100,000 | 1,521,900,000 | 8,292,500,000 | 2,485,800,000 | 5,806,700,000 | 1,218,200,000 |
TTM Snapshot
Revenues TTM
$5,329,500,000
NetIncome TTM
$4,157,200,000
OpCashFlow TTM
$0
Assets (Latest)
$13,697,200,000
Forward EPS
$3.38
Max Pain — expiry 2027-01-15
max pain strike: $70.00 · spot: $85.19 · call oi: 68 · put oi: 10,537
Expected Move to 2027-01-15:
±$11.53
(13.53%) —
implied range
$73.66 –
$96.72
· ATM straddle on $85.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDX | BECTON DICKINSON & CO | $48.50B | $178.07 | — |
| BSX | BOSTON SCIENTIFIC CORP | $62.65B | $43.23 | — |
| DXCM | DEXCOM INC | $32.54B | $86.23 | — |
| RMD | RESMED INC | $31.90B | $221.15 | — |
| MDLN | Medline Inc. | $30.65B | $34.94 | — |
News headlines (Yahoo Finance, 1h cache)
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
2026-10-01 20:26 · Yahoo
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions
2026-09-18 22:15 · Yahoo
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
2026-09-17 11:02 · Yahoo
CMS expands TAVR Medicare coverage to asymptomatic patients
2026-09-11 12:14 · Yahoo
Is Edwards Lifesciences Stock Underperforming the Dow?
2026-09-08 09:20 · Yahoo
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
2026-09-02 20:15 · Yahoo
Unusual Volume in Edwards Lifesciences Put Options Shows Investors Bullish on EW Stock
2026-08-31 17:30 · Yahoo
Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?
2026-08-20 23:12 · Yahoo
Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion
2026-09-18 18:12 · Yahoo
Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031
2026-09-18 10:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.